Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Lepu Biopharma Co. Ltd. Class H (2157) Stock Price & Analysis

4 Followers

2157 Stock Chart & Stats

HK$2.92-HK$0.04(-1.35%)
At close: 4:00 PM GMT+8
HK$3HK$3.5HK$4HK$4.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 2.85 - HKD 2.96
52-Week Range
HKD 2.77 - HKD 6.65
Previous Close
HKD 2.96
Volume
N/A
Average Volume (3M)
11.20M
Market Cap
HKD 5.34B
Enterprise Value
HKD 7.44B
Total Cash (Recent Filing)
HKD 788.84M
Total Debt (Recent Filing)
HKD 1.18B
Price to Earnings (P/E)
18.4
Beta
0.55
Next Earnings
Mar 31, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Revenue And Profit Inflection

The 2025 revenue surge and shift to a sizable profit indicate that Lepu Biopharma has achieved meaningful commercial scale after earlier development-stage losses. If this operating inflection persists, it can strengthen internal funding capacity and support continued investment in oncology growth.

High Gross Margins

Sustained gross margins above 80% point to attractive economics on the company’s marketed or partnered products and provide substantial room to absorb operating costs. This margin structure can support reinvestment in research, commercialization, and pipeline expansion if revenue remains durable.

Improving Equity Returns

The return to positive ROE suggests that the 2025 earnings improvement translated into more productive use of shareholder capital. Combined with equity expansion and a lower debt-to-equity ratio than in 2024, this indicates improving financial efficiency and a stronger base for future growth.

Bears Say

Negative Cash Conversion

Negative operating and free cash flow while reporting a sizable profit shows that earnings are not yet converting reliably into liquidity. Continued cash deficits could require external funding, constrain research and commercialization spending, and increase financial risk during the next development cycle.

Meaningful Debt Load

Although the debt-to-equity ratio improved as equity expanded, the absolute increase in total debt leaves the company exposed to financing obligations. A meaningful debt burden can reduce flexibility to fund pipeline opportunities and create greater pressure if earnings or cash generation weaken.

Unproven Turnaround Durability

The sharp 2025 improvement follows several years of substantial losses and limited earlier revenue, so the current earnings level has not yet been established as a stable multi-year trend. This history raises execution risk around sustaining commercialization, margins, and profitability.

Lepu Biopharma Co. Ltd. Class H News

2157 FAQ

What was Lepu Biopharma Co. Ltd. Class H’s price range in the past 12 months?
Lepu Biopharma Co. Ltd. Class H lowest stock price was HK$2.77 and its highest was HK$6.65 in the past 12 months.
What is Lepu Biopharma Co. Ltd. Class H’s market cap?
Lepu Biopharma Co. Ltd. Class H’s market cap is HK$5.34B.
When is Lepu Biopharma Co. Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lepu Biopharma Co. Ltd. Class H’s earnings last quarter?
Lepu Biopharma Co. Ltd. Class H released its earnings results on Aug 19, 2026. The company reported HK$0.023 earnings per share for the quarter.
Is Lepu Biopharma Co. Ltd. Class H overvalued?
According to Wall Street analysts Lepu Biopharma Co. Ltd. Class H’s price is currently Undervalued.
Does Lepu Biopharma Co. Ltd. Class H pay dividends?
Lepu Biopharma Co. Ltd. Class H does not currently pay dividends.
What is Lepu Biopharma Co. Ltd. Class H’s EPS estimate?
Lepu Biopharma Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lepu Biopharma Co. Ltd. Class H have?
Lepu Biopharma Co. Ltd. Class H has 1,804,439,800 shares outstanding.
What happened to Lepu Biopharma Co. Ltd. Class H’s price movement after its last earnings report?
Lepu Biopharma Co. Ltd. Class H reported an EPS of HK$0.023 in its last earnings report. Following the earnings report the stock price went down -3.656%.
Which hedge fund is a major shareholder of Lepu Biopharma Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2157
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology